Genosco, Inc.

With the long-awaited global commercialization of lazertinib, Oscotec Inc. and its US subsidiary Genosco, the originators of the novel lung cancer drug, are poised to see a steady inflow of revenues

A series of initial public offering plans unveiled by South Korean biopharma firms, notably Orum Therapeutics Inc., is raising hopes of a recovery in the general funding situation in the sector. After

Johnson & Johnson announced significant positive updated and new data for Rybrevant (amivantamab) with lazertinib in first-line non-small cell lung cancer (NSCLC) at the American Society of Clinical

While the South Korean biotech industry appears to be in a temporary slowdown, investment funds remain solid and expectations are rising amid active convergence between biotechnology and IT. Although